Non-coding RNA for early diagnosis of laryngeal squamous cell carcinoma

Abstract

The invention discloses a molecular marker which can be used for diagnosing laryngeal squamous cell carcinoma. The marker is LOC100507002. By detecting the level of the LOC100507002 in the suspected diseased tissue of a subject, the invention can judge whether the subject suffers from laryngeal squamous cell carcinoma or not or whether the subject has the risk of suffering from laryngeal squamouscell carcinoma. According to the LOC100507002, a product for diagnosing laryngeal squamous cell carcinoma by detecting the content of the LOC100507002 can be developed, and the diagnosis product can be popularized and used clinically.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to a non-coding RNA for early diagnosis of laryngeal squamous cell carcinoma. Background technique [0002] Laryngeal cancer is a common malignant tumor in the head and neck, accounting for the second place in head and neck tumors, and its incidence rate accounts for about 5% of systemic malignant tumors. Most squamous cell carcinomas originate in the vocal cords, accounting for about 60%. Huang Xinhui et al conducted a retrospective analysis on 306 cases of laryngeal malignant tumors and found that squamous cell carcinoma accounted for 99.7% of all malignant tumors, among which squamous cell carcinoma with high and moderate differentiation was the main type; the primary site of laryngeal cancer was mostly glottic type, Followed by supraglottic type, subglottic type; smoking, drinking are closely related to the occurrence of tumors. Although surgery, radiotherapy, and chemotherapy can alle...

AI Technical Summary

Problems solved by technology

The reasons are mainly manifested in three aspects: First, the early clinical manifestations of laryngeal cancer are diverse, which brings great difficulty to the early diagnosis of laryngeal cancer. Most patients fail to receive timely and effective treatment in the early stage. Molecular markers are the key to improving the early diagnosis rate of laryngeal cancer

Second, the treatment of laryngeal cancer is mainly based on surgery, supplemented by radiotherapy and chemotherapy. Although partial laryngectomy and the early stage of glottic laryngeal cancer are treated with C02 laser treatment, the laryngeal function is completely or partially preserved, and postoperative complications Therefore, the quality of life of patients is improved, but the postoperative recurrence rate is still high. If the tumor-promoting genes or tumor suppressor factors of laryngeal cancer can be found out, and potential drug targets can be screened out, it will be a great opportunity for the development of laryngeal cancer. Cancer-related specific vaccines or / and new anti-cancer drugs lay the foundation

Images